Cart
sales@molnova.com
Spiroplatin
CAS No. 74790-08-2
Spiroplatin( —— )
Catalog No. M36228 CAS No. 74790-08-2
Spiroplatin (TNO-6) is a novel platinum-containing analogue with antitumor activity that is commonly used in the study of solid tumors.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 296 | Get Quote |
|
| 5MG | 459 | Get Quote |
|
| 10MG | 657 | Get Quote |
|
| 25MG | 994 | Get Quote |
|
| 50MG | 1371 | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameSpiroplatin
-
NoteResearch use only, not for human use.
-
Brief DescriptionSpiroplatin (TNO-6) is a novel platinum-containing analogue with antitumor activity that is commonly used in the study of solid tumors.
-
DescriptionSpiroplatin (TNO-6) is a novel platinum-containing analogue with antitumor activity that is commonly used in the study of solid tumors.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number74790-08-2
-
Formula Weight433.39
-
Molecular FormulaC8H18N2O4PtS
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESO=S1(=O)[O-][Pt+2]2([O-]1)[NH2]CC3(CCCCC3)C[NH2]2
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
-
Citrusin B
Citrusin B exhibits moderate in vitro inhibitory effect on tobacco mosaic virus replication with IC50 values 0.26?mmol?L?1.
-
Azido-PEG1-CH2CO2H
Azido-PEG1-CH2CO2H is a PROTAC linker that refers to an alkyl/ether combination. Azido-PEG1-CH2CO2H can be used to synthesize PROTAC BRD4 Degrader-1.
-
Syk Inhibitor II hyd...
The impact of spleen tyrosine kinase (Syk) signaling might be prominent in lupus because (i) Syk is a shared downstream signaling molecule among circulating immune complex, LPS, and (1→3)-β-D-glucan (BG), and (ii) all of these factors are detectable in the serum of Fc gamma receptor IIb-deficient (FcgRIIb-/-) mice with sepsis. Syk inhibition downregulated several inflammatory pathways in FcgRIIb-/- macrophages activated with BG + LPS suggesting the potential anti-inflammatory impact of Syk inhibitors in lupus.
